Johnson & Johnson (NYSE:JNJ) received a $133.00 price target from investment analysts at RBC Capital Markets in a research note issued on Wednesday. The firm currently has a a “buy” rating on the stock. RBC Capital Markets’ target price points to a potential upside of 11.26% from the stock’s current price.

Other analysts have also recently issued reports about the company. Jefferies Group boosted their target price on Johnson & Johnson from $109.00 to $113.00 and gave the stock a “hold” rating in a research report on Thursday, July 14th. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $125.00 to $133.00 and gave the company an “outperform” rating in a research report on Wednesday, July 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $132.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Leerink Swann reiterated an “outperform” rating and issued a $140.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Finally, Deutsche Bank AG reiterated a “hold” rating and issued a $142.00 price objective (up from $125.00) on shares of Johnson & Johnson in a research report on Thursday, July 21st. Two equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $120.79.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Johnson & Johnson (NYSE:JNJ) opened at 119.54 on Wednesday. The firm’s 50-day moving average is $117.11 and its 200 day moving average is $118.12. The stock has a market capitalization of $327.05 billion, a P/E ratio of 20.98 and a beta of 0.75. Johnson & Johnson has a 12 month low of $94.28 and a 12 month high of $126.07.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The firm had revenue of $17.80 billion for the quarter, compared to the consensus estimate of $17.71 billion. During the same quarter in the previous year, the company earned $1.49 earnings per share. The business’s revenue was up 4.2% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post $6.72 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Investors of record on Tuesday, November 22nd will be paid a $0.80 dividend. The ex-dividend date of this dividend is Friday, November 18th. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $0.29. This represents a $3.20 annualized dividend and a yield of 2.68%. Johnson & Johnson’s dividend payout ratio (DPR) is 56.64%.

In related news, Director Charles Prince acquired 875 shares of the stock in a transaction dated Friday, October 21st. The stock was bought at an average cost of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the transaction, the director now directly owns 26,520 shares of the company’s stock, valued at $3,026,197.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.11% of the stock is owned by company insiders.

A number of large investors have recently made changes to their positions in JNJ. Nisa Investment Advisors L.L.C. boosted its position in shares of Johnson & Johnson by 0.4% in the first quarter. Nisa Investment Advisors L.L.C. now owns 931,130 shares of the company’s stock valued at $100,748,000 after buying an additional 3,630 shares during the last quarter. Virginia Retirement System bought a new position in shares of Johnson & Johnson during the first quarter valued at about $119,842,000. BTC Capital Management Inc. boosted its position in shares of Johnson & Johnson by 15.9% in the first quarter. BTC Capital Management Inc. now owns 57,100 shares of the company’s stock valued at $6,169,000 after buying an additional 7,832 shares during the last quarter. Dynamic Advisors Solutions LLC boosted its position in shares of Johnson & Johnson by 0.8% in the first quarter. Dynamic Advisors Solutions LLC now owns 12,095 shares of the company’s stock valued at $1,309,000 after buying an additional 91 shares during the last quarter. Finally, American Economic Planning Group Inc. ADV boosted its position in shares of Johnson & Johnson by 6.6% in the first quarter. American Economic Planning Group Inc. ADV now owns 25,202 shares of the company’s stock valued at $2,727,000 after buying an additional 1,564 shares during the last quarter. 65.34% of the stock is owned by hedge funds and other institutional investors.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company’s segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women’s health and wound care markets.

5 Day Chart for NYSE:JNJ

Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.